Last Updated: October 1, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Eurasian Patent Organization: These 31 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Generic Entry Dates in Other Countries

African Regional IP Organization (ARIPO) Argentina Australia Austria Brazil Canada Chile China Colombia Costa Rica Croatia Cuba Cyprus Denmark Dominican Republic Ecuador European Patent Office Finland France Georgia, Republic of Germany Guatemala Honduras Hong Kong Hungary Israel Italy Japan Jordan Lithuania Luxembourg Malaysia Mexico Montenegro Morocco Netherlands New Zealand Nicaragua Norway Panama Peru Philippines Poland Portugal Russian Federation San Marino Saudi Arabia Serbia Singapore Slovenia South Africa South Korea Spain Taiwan Tunisia Turkey Ukraine United Kingdom United States Uruguay
Preferred citation:
Friedman, Yali, "Eurasian Patent Organization: These 31 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can COTELLIC (cobimetinib fumarate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: cobimetinib fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 05, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 19,983

COTELLIC is a drug marketed by Genentech Inc. There are seven patents protecting this drug.

See drug price trends for COTELLIC.

The generic ingredient in COTELLIC is cobimetinib fumarate. Additional details are available on the cobimetinib fumarate profile page.

When can COTELLIC (cobimetinib fumarate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: cobimetinib fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 05, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 32,466

COTELLIC is a drug marketed by Genentech Inc. There are seven patents protecting this drug.

See drug price trends for COTELLIC.

The generic ingredient in COTELLIC is cobimetinib fumarate. Additional details are available on the cobimetinib fumarate profile page.

When can COTELLIC (cobimetinib fumarate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: cobimetinib fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 05, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,801,041

COTELLIC is a drug marketed by Genentech Inc. There are seven patents protecting this drug.

See drug price trends for COTELLIC.

The generic ingredient in COTELLIC is cobimetinib fumarate. Additional details are available on the cobimetinib fumarate profile page.

When can COTELLIC (cobimetinib fumarate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: cobimetinib fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 05, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,400,111

COTELLIC is a drug marketed by Genentech Inc. There are seven patents protecting this drug.

See drug price trends for COTELLIC.

The generic ingredient in COTELLIC is cobimetinib fumarate. Additional details are available on the cobimetinib fumarate profile page.

When can COTELLIC (cobimetinib fumarate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: cobimetinib fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 05, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,691,142

COTELLIC is a drug marketed by Genentech Inc. There are seven patents protecting this drug.

See drug price trends for COTELLIC.

The generic ingredient in COTELLIC is cobimetinib fumarate. Additional details are available on the cobimetinib fumarate profile page.

When can COTELLIC (cobimetinib fumarate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: cobimetinib fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 05, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,990,219

COTELLIC is a drug marketed by Genentech Inc. There are seven patents protecting this drug.

See drug price trends for COTELLIC.

The generic ingredient in COTELLIC is cobimetinib fumarate. Additional details are available on the cobimetinib fumarate profile page.

When can ZTALMY (ganaxolone) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ganaxolone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 17,290
Patent Title: КОМПОЗИЦИИ НА ОСНОВЕ ГАНАКСОЛОНА (GANAXOLONE-BASED FORMULATIONS)

ZTALMY is a drug marketed by Immedica Pharma. There are eleven patents protecting this drug. There has been litigation on patents covering ZTALMY

See drug price trends for ZTALMY.

The generic ingredient in ZTALMY is ganaxolone. Additional details are available on the ganaxolone profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 17,091

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,970,532

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 17,252

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 19,941

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 19,966

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,970,557

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,100,687

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,100,688

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,970,575

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 18,545
Patent Title: ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ (THERAPEUTIC COMPOSITIONS)

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 24,152
Patent Title: КОМПОЗИЦИЯ ДЛЯ МЕСТНОГО ВВЕДЕНИЯ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА КОЖИ (TOPICAL COMPOSITION FOR TREATING OR PREVENTING SKIN CANCER)

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,870,063
Patent Title: ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,201,452
Patent Title: ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 27,573

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 34,598

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,870,116

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,790,678

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can EPSOLAY (benzoyl peroxide) generic drug versions launch in the Eurasian Patent Organization?

Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 18,275
Patent Title: СПОСОБ ПОЛУЧЕНИЯ ЧАСТИЦ, СОДЕРЖАЩИХ ПОКРЫТИЕ ИЗ ОКСИДА МЕТАЛЛА, И ЧАСТИЦЫ С ПОКРЫТИЕМ ИЗ ОКСИДА МЕТАЛЛА (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING)

Drug Price Trends for EPSOLAY
EPSOLAY is a drug marketed by Mayne Pharma. There are fourteen patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering EPSOLAY

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. Additional details are available on the benzoyl peroxide profile page.

When can EPSOLAY (benzoyl peroxide) generic drug versions launch in the Eurasian Patent Organization?

Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,970,725
Patent Title: СПОСОБ ПОЛУЧЕНИЯ ЧАСТИЦ, СОДЕРЖАЩИХ ПОКРЫТИЕ ИЗ ОКСИДА МЕТАЛЛА, И ЧАСТИЦЫ С ПОКРЫТИЕМ ИЗ ОКСИДА МЕТАЛЛА (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING)

Drug Price Trends for EPSOLAY
EPSOLAY is a drug marketed by Mayne Pharma. There are fourteen patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering EPSOLAY

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. Additional details are available on the benzoyl peroxide profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 15,180

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,970,726

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 18,707

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,970,868

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can EDARBI (azilsartan kamedoxomil) generic drug versions launch in the Eurasian Patent Organization?

Generic name: azilsartan kamedoxomil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 16,593
Patent Title: ТВЕРДАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ ПРОИЗВОДНОЕ БЕНЗИМИДАЗОЛ-7-КАРБОКСИЛАТА И pH РЕГУЛИРУЮЩИЙ АГЕНТ (SOLID PHARMACEUTICAL COMPOSITION COMPRISING A BENZIMIDAZOLE-7-CARBOXYLATE DERIVATIVE AND A PH CONTROL AGENT)

Drug Price Trends for EDARBI
EDARBI is a drug marketed by Azurity. There is one patent protecting this drug. There has been litigation on patents covering EDARBI

See drug price trends for EDARBI.

The generic ingredient in EDARBI is azilsartan kamedoxomil. Additional details are available on the azilsartan kamedoxomil profile page.

When can TRADJENTA (linagliptin) generic drug versions launch in the Eurasian Patent Organization?

Generic name: linagliptin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 30, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 29,890

Drug Price Trends for TRADJENTA
TRADJENTA is a drug marketed by Boehringer Ingelheim. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market. There has been litigation on patents covering TRADJENTA

See drug price trends for TRADJENTA.

The generic ingredient in TRADJENTA is linagliptin. Additional details are available on the linagliptin profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in the Eurasian Patent Organization?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 20,883

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in the Eurasian Patent Organization?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 34,294

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in the Eurasian Patent Organization?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,400,387

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in the Eurasian Patent Organization?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,991,590

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,870,514

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,870,515

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 17,270

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,971,046

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 18,203

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 19,284

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,971,132

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 19,284

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,971,132

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can XADAGO (safinamide mesylate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: safinamide mesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 08, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 25,326

Drug Price Trends for XADAGO
XADAGO is a drug marketed by Mdd Us. There are three patents protecting this drug. There has been litigation on patents covering XADAGO

See drug price trends for XADAGO.

The generic ingredient in XADAGO is safinamide mesylate. Additional details are available on the safinamide mesylate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 19,784

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,070,013

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in the Eurasian Patent Organization?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 20,806
Patent Title: СИНТЕТИЧЕСКАЯ ДЕЗОКСИХОЛЕВАЯ КИСЛОТА И КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ, СОЕДИНЕНИЯ И СПОСОБ ПОЛУЧЕНИЯ ДЕЗОКСИХОЛЕВОЙ КИСЛОТЫ, СПОСОБ УДАЛЕНИЯ ЖИРОВЫХ ОТЛОЖЕНИЙ (METHOD FOR PRERARING DEOXYCHOLIC ACID (EMBODIMENTS), DEOXYCHOLIC ACID PREPARED BY SAID METHOD, PHARMACEUTICAL COMPOSITION CONTAINING SAME, METHOD FOR REMOVAL OF FAT DEPOSITS)

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in the Eurasian Patent Organization?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,000,032
Patent Title: СПОСОБ ПОЛУЧЕНИЯ ДЕЗОКСИХОЛЕВОЙ КИСЛОТЫ (ВАРИАНТЫ), ДЕЗОКСИХОЛЕВАЯ КИСЛОТА, ПОЛУЧЕННАЯ УКАЗАННЫМ СПОСОБОМ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЕЕ СОДЕРЖАЩАЯ, СПОСОБ УДАЛЕНИЯ ЖИРОВЫХ ОТЛОЖЕНИЙ (METHOD FOR PRERARING DEOXYCHOLIC ACID (EMBODIMENTS), DEOXYCHOLIC ACID PREPARED BY SAID METHOD, PHARMACEUTICAL COMPOSITION CONTAINING SAME, METHOD FOR REMOVAL OF FAT DEPOSITS)

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can TWIRLA (ethinyl estradiol; levonorgestrel) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ethinyl estradiol; levonorgestrel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 20,208
Patent Title: УСТРОЙСТВО ДОСТАВКИ В КОЖУ С ИЗОЛИРУЮЩИМ СЛОЕМ IN SITU (DERMAL DELIVERY DEVICE WITH IN SITU SEAL)

Drug Price Trends for TWIRLA
TWIRLA is a drug marketed by Agile. There are three patents protecting this drug. Two tentatively approved generics are ready to enter the market.

See drug price trends for TWIRLA.

The generic ingredient in TWIRLA is ethinyl estradiol; levonorgestrel. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.

When can TWIRLA (ethinyl estradiol; levonorgestrel) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ethinyl estradiol; levonorgestrel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,070,123
Patent Title: УСТРОЙСТВО ДОСТАВКИ В КОЖУ С ИЗОЛИРУЮЩИМ СЛОЕМ IN SITU (DERMAL DELIVERY DEVICE WITH IN SITU SEAL)

Drug Price Trends for TWIRLA
TWIRLA is a drug marketed by Agile. There are three patents protecting this drug. Two tentatively approved generics are ready to enter the market.

See drug price trends for TWIRLA.

The generic ingredient in TWIRLA is ethinyl estradiol; levonorgestrel. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 17,281
Patent Title: ПРОИЗВОДНЫЕ ПИРИМИДИНИЛ-ПИРИДАЗИНОНА (PYRIMIDINYL PYRIDAZINONE DERIVATES)

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,000,093
Patent Title: ПРОИЗВОДНЫЕ ПИРИДАЗИНОНА (PYRIDAZINONE DERIVATES)

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,000,094
Patent Title: ПРОИЗВОДНЫЕ ПИРИМИДИНИЛПИРИДАЗИНОНА (PYRIMIDINYL PYRIDAZINONE DERIVATES)

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can KAZANO (alogliptin benzoate; metformin hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 19, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 20,870

Drug Price Trends for KAZANO
KAZANO is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KAZANO

See drug price trends for KAZANO.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.

When can KAZANO (alogliptin benzoate; metformin hydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 19, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,070,164

Drug Price Trends for KAZANO
KAZANO is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KAZANO

See drug price trends for KAZANO.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in the Eurasian Patent Organization?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 01, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,971,018

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch in the Eurasian Patent Organization?

Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 09, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,900,298
Patent Title: ИНГИБИТОРЫ ВИРУСА ГЕПАТИТА С (HEPATITIS C VIRUS INHIBITORS)

Drug Price Trends for DAKLINZA
DAKLINZA is a drug marketed by Bristol-myers Squibb. There are five patents protecting this drug. There has been litigation on patents covering DAKLINZA

See drug price trends for DAKLINZA.

The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. Additional details are available on the daclatasvir dihydrochloride profile page.

When can INTRAROSA (prasterone) generic drug versions launch in the Eurasian Patent Organization?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 20,683
Patent Title: КОМПОЗИЦИИ DHEA ДЛЯ ЛЕЧЕНИЯ МЕНОПАУЗЫ (METHOD FOR TREATING OR REDUCING ACQUIRING SYMPTOMS OR DISEASES IN POSTMENOPAUSAL WOMEN, INTRAVAGINAL COMPOSITION AND SUPPOSITORY USED THEREIN)

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can INTRAROSA (prasterone) generic drug versions launch in the Eurasian Patent Organization?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,000,312
Patent Title: СПОСОБ ЛЕЧЕНИЯ ИЛИ УМЕНЬШЕНИЯ РИСКА ВОЗНИКНОВЕНИЯ СИМПТОМОВ ИЛИ ЗАБОЛЕВАНИЙ У ПОСТМЕНОПАУЗНЫХ ЖЕНЩИН, ИНТРАВАГИНАЛЬНАЯ КОМПОЗИЦИЯ И СУППОЗИТОРИЙ, ПРИМЕНЯЕМЫЕ В НЕМ (METHOD FOR TREATING OR REDUCING ACQUIRING SYMPTOMS OR DISEASES IN POSTMENOPAUSAL WOMEN, INTRAVAGINAL COMPOSITION AND SUPPOSITORY USED THEREIN)

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can INTRAROSA (prasterone) generic drug versions launch in the Eurasian Patent Organization?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,200,369
Patent Title: ПРИМЕНЕНИЕ ПРЕДШЕСТВЕННИКОВ ПОЛОВЫХ СТЕРОИДНЫХ ГОРМОНОВ В КОМБИНАЦИИ С СЕЛЕКТИВНЫМ МОДУЛЯТОРОМ ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ И СОСТОЯНИЙ У ПОСТМЕНОПАУЗНЫХ ЖЕНЩИН

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in the Eurasian Patent Organization?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 17,405

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 17,824
Patent Title: АНТИБАКТЕРИАЛЬНЫЕ АНАЛОГИ АМИНОГЛИКОЗИДА (ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS)

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in the Eurasian Patent Organization?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,070,597
Patent Title: АНТИБАКТЕРИАЛЬНЫЕ АНАЛОГИ АМИНОГЛИКОЗИДА (ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS)

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in the Eurasian Patent Organization?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 18,193

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in the Eurasian Patent Organization?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 23,500

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in the Eurasian Patent Organization?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,100,440

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in the Eurasian Patent Organization?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,100,441

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in the Eurasian Patent Organization?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,270,666

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in the Eurasian Patent Organization?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 18,193

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in the Eurasian Patent Organization?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 23,500

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in the Eurasian Patent Organization?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,100,440

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in the Eurasian Patent Organization?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,100,441

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in the Eurasian Patent Organization?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,270,666

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

Eurasian Patent Organization (EAPO) Branded vs Generic Drug Markets: Regulatory Opportunities, Patent Barriers, and Entry Timing

Last updated: May 12, 2026

Branded and generic drug markets across Eurasia are shaped by EAPO patent coverage, national enforcement in member states, and drug-regulatory fit for each pathway. Opportunities cluster where patent estates are narrow (single substance or limited formulations) and where the regulator accepts bridging evidence for generics. Challenges concentrate in patent density (process and formulation), enforcement realism (injunction risk and timing), and regulator-adjacent exclusivities (originator data protection) that can delay first-to-file generics even when patent terms are near expiry.

What is the Eurasian Patent Organization (EAPO) and how does it affect branded vs generic drug competition?

The Eurasian Patent Organization administers the Eurasian patent system, including the Eurasian patent (EAP) route that can cover multiple member states in one application. For pharma strategy, the key impact is whether an originator holds enforceable patent rights that a generic must clear across the EAPO-designated states.

Which countries participate in the Eurasian patent system for pharma enforcement?

EAPO member states drive where patent rights can be enforced in national courts or via national mechanisms. Pharma clearance and litigation planning must map patent coverage to each market.

Practical market mapping for EAPO strategy (high-level):

  • Russia: largest market, highest patent enforcement activity.
  • Belarus, Kazakhstan, Armenia, Kyrgyzstan: meaningful access depending on procurement and reimbursement.
  • Others in regional trade flows: may receive downstream effects via supply chains even when not top priority for filing.

(For market work, the core workstream is always: which EAPO-designated states have the active patent portfolio and which ones host generic competitors.)

How do EAPO patents influence generic filing choices?

Generic entry decisions pivot on three variables:

  1. Patent scope: compound, formulation, process, and method-of-use claims.
  2. Jurisdictional enforceability: whether the patent is active and enforceable in the target state.
  3. Regulatory exclusivity and dossier protections: whether the regulator will accept generic dossiers without waiting periods.

How competitive are branded and generic drug markets across Eurasia by regulatory and patent headwinds?

Competition intensity in Eurasia is driven by a mix of:

  • import and local manufacturing capacity,
  • reimbursement and tender dynamics,
  • and how quickly generics can be launched after regulatory authorization.

Where generics tend to win faster in Eurasia

Generics typically accelerate when at least one of the following is true:

  • the originator’s patent estate in key states is limited to early compound claims that expire,
  • the originator relies on broad but weakly supported formulation/process claims that are difficult to enforce,
  • the regulatory pathway allows well-documented bioequivalence or bridging (depending on product category and evidence standards).

Where branded products hold market share longer

Branded retention is most common when:

  • originators file dense patent sets (process + formulation + polymorph or salt forms),
  • exclusivity-like protections extend beyond patent expiry in practice (data protection periods and marketing rules),
  • supply continuity and quality systems create procurement lock-in.

Commercial risk pattern for investors and licensors

In the Eurasian context, a common failure mode is overestimating “patent expiry equals immediate generic entry.” Actual timing is governed by:

  • clearing of the last enforceable patent claim,
  • regulatory acceptance timelines,
  • and practical litigation or administrative delays.

What patents protect branded drugs in Eurasia and how many layers of IP do generics face?

Eurasian pharma patent portfolios frequently include multi-layer protections. A generic is usually required to address at least one of:

  • substance/compound claims,
  • salt/polymorph/hydrate claims,
  • formulation claims (excipients, particle size, coating, release profile),
  • manufacturing/process claims,
  • and sometimes method-of-use claims when supported by data.

Typical EAPO-aligned patent estate layers for small-molecule drugs

Layer 1: compound and salt forms

  • claims to active ingredient and specific salts/hydrates.

Layer 2: formulation and dosage form

  • solid dispersion, controlled release matrix, specific excipient system, particle-size distributions.

Layer 3: process

  • synthesis route, purification steps, crystallization conditions.

Layer 4: method-of-use

  • dosing regimens or therapeutic uses, where supported.

Typical estate layers for biologics and complex products

Biologics generally face:

  • substance/process patents,
  • manufacturing cell line and process conditions,
  • and formulation-related claims tied to stability.

For biosimilars, the “patent clearance” problem is still present, but the regulator and evidence requirements drive additional time and cost.

What is the typical expiration and exclusivity timeline for branded drugs in Eurasia?

Featured-snippet answer: In Eurasia, the generic entry timeline is a function of both patent term (often multiple years depending on filings and claim scope) and regulatory protection periods that can delay authorization or market launch even after some patents expire.

Key timeline drivers used in clearance planning

  1. Earliest priority date and patent grant timeline
  2. Family strategy: continuation-like strategies, divisional equivalents, and follow-on filings.
  3. Jurisdiction mapping: active status by state within the EAPO coverage.
  4. Regulatory protection: data protection and related marketing safeguards.
  5. Litigation duration: injunction risk and court timelines.

How to model entry timing for generics

Market entry models are typically built with three checkpoints:

  • Regulatory readiness (dossier acceptance and bioequivalence readiness)
  • IP clearance (avoid infringement or secure non-infringement/invalidity positioning)
  • Commercial ramp (tender cycles and procurement schedules)

When does generic competition become viable after EAPO patent expiry in key states?

Generic viability depends on whether the last enforceable patent layer is cleared. In many portfolios, the “final barrier” is a formulation or process claim rather than the original compound claim.

Typical “last patent standing” areas

  • controlled release technologies,
  • specific excipient systems,
  • manufacturing crystallization and drying conditions,
  • polymorphs/salt forms with improved stability.

Practical entry windows

A generic often targets one of two windows:

  • Safe launch window: after the last enforceable claim expiry.
  • Challenge-driven window: launch after a successful patent challenge or a settlement that authorizes earlier entry.

How do Paragraph IV-style challenges work in Eurasia, and what is the generic litigation pathway?

Eurasia does not operate a single standardized “Paragraph IV” system comparable to the US Hatch-Waxman framework. Generic challenges and litigation typically proceed through:

  • invalidity actions,
  • non-infringement defenses,
  • and court-based relief such as injunctions.

Settlement dynamics

In practice, originators and generics can settle to control timing and reduce uncertainty, but the settlement mechanics vary by national enforcement system.

What litigation changes for generics after filing

Once a generic is authorized, enforcement risk remains. The main risk for generics is an injunction that can block supply even when the authorization exists.

What is the Orange Book status of EAPO drugs and how do you find patent listings for market entry?

Eurasia does not use the US FDA Orange Book model. Market authorization dossiers and patent information access are handled through national systems and ad hoc registry structures.

Compliance workflow for Eurasian patent clearance

  • Pull active patent families relevant to the marketed drug in each target state.
  • Map marketed strength and dosage form to formulation and process claims.
  • Confirm whether the generic’s planned product design stays outside claim coverage.

Which companies are challenging EAPO-covered drug patents and how does the competitive landscape look?

The competitive landscape across Eurasia features:

  • multinational originators with active regional patent filing,
  • local and regional generic manufacturers,
  • and distributors that shape procurement outcomes.

Competition by category

Small-molecule generics

  • face compound/formulation/process estate clearance,
  • typically target “patent-skim” portfolios where follow-on patents are weaker or expired.

Biosimilars and complex biologics

  • face broader patent families tied to manufacturing and characterization,
  • regulatory evidence requirements can slow entry even where patents expire.

What formulations are protected by EAPO patents and which generic product design choices reduce infringement risk?

Formulation and dosage form claims are a major barrier in Eurasia, especially for:

  • controlled release tablets,
  • enteric-coated forms,
  • extended-release systems,
  • and particle-engineered solids.

Generic design-around approaches that commonly matter

  • selecting alternative salts/polymorphs not covered by the claim set,
  • altering excipient system composition and ratios if claims are narrow enough,
  • changing manufacturing process parameters that drive different crystal forms or particle sizes,
  • using different release profiles that avoid controlled-release claim scope.

How strong is the patent estate for branded drugs in Eurasia and what makes it defensible?

A strong patent estate is usually characterized by:

  • clear, narrow claim language tied to measurable properties,
  • multiple active filings covering different aspects (compound + formulation + process),
  • evidence support for enabled claims,
  • and enforceability across multiple key jurisdictions.

Signals that generics face higher clearance risk

  • many follow-on filings within short intervals,
  • claims that cover both the active ingredient and the dosage form,
  • process claims with specific parameter windows,
  • and patent families where at least one key claim survives in each target state.

What patent litigation affects generic launch scenarios in Eurasia?

Litigation affects both timing and product economics:

  • injunction risk can block supply even if authorization is in place,
  • court timelines can extend beyond expected commercial launch windows,
  • settlement payments or licensing terms can reshape margins.

Typical litigation endpoints

  • invalidation of specific claims,
  • narrowing claim scope through interpretation,
  • or settlement that authorizes earlier supply with constraints.

What regulatory opportunities exist for generics in Eurasia under data protection and bridging rules?

Regulatory opportunity concentrates where generics can leverage:

  • established bioequivalence frameworks,
  • acceptable bridging for comparable strengths and dosage forms,
  • and clear dossier pathways for authorized generics.

Where regulatory bottlenecks typically slow launch

  • incomplete product comparability evidence,
  • complex dosage forms where equivalence must be demonstrated beyond simple bioequivalence,
  • biologics where characterization and comparability requirements are heavier.

How do biosimilar risks differ from generic risks across Eurasia?

Biosimilars face both:

  • broader patent estates (manufacturing, characterization, process),
  • and regulator-required evidence that can be more time-consuming.

Biosimilar “time-to-market” risk pattern

  • patent clearance disputes run longer,
  • evidence generation costs are higher,
  • and settlement or delayed launches are more common when the originator has dense manufacturing IP.

Which commercial strategies work best: licensing, co-development, or direct generic entry in EAPO markets?

Licensing
Best when originators hold dense estates and litigation costs for generics are prohibitive.

Co-development and technology transfer
Works when process/formulation IP is the dominant barrier; it converts infringement risk into contracted know-how.

Direct entry
Works when:

  • the patent estate is thin,
  • regulatory authorization is achievable quickly,
  • and litigation risk can be priced or avoided via design-around.

Key Takeaways

  • EAPO patent coverage can meaningfully delay generic entry, but the real timing driver is the last enforceable patent layer across key states, often formulation or process claims.
  • Eurasian branded share retention is typically sustained by multi-layer patent estates plus procurement and evidence-driven regulatory friction for generics.
  • The highest-return opportunities for entrants are in portfolios where:
    • compound claims have expired or are weak in the target states, and
    • formulation/process claims are narrow enough to design around.
  • Litigation risk in Eurasia is a launch-timing constraint: authorization does not eliminate injunction exposure.
  • Biosimilars carry higher “evidence + IP” load than small-molecule generics, making licensing or settlement more common.

FAQs

1) How should a generic applicant in Eurasia structure a product design-around when formulation patents block entry?
By mapping the planned excipient system, particle size distribution, salt/polymorph selection, and release profile to claim elements, then selecting a combination that avoids the narrowest enforceable limitations first.

2) What is the highest-risk IP category for generics in Eurasia: compound, formulation, or process?
Formulation and process are often the highest-risk categories because they survive follow-on filings and can cover the marketed dosage form even after compound expiry.

3) Does regulatory authorization in Eurasia guarantee market freedom from patent enforcement?
No. Patent enforcement can still restrict supply through injunctions or other court relief.

4) What makes biosimilar entry slower than generic entry in EAPO member states?
Biosimilar evidence requirements are heavier and the patent estate often includes manufacturing and characterization claims, increasing both regulatory and IP clearance time.

5) When do licensing deals most frequently occur in Eurasian branded markets?
When the originator has dense follow-on patents and the generic’s design-around is technically constrained or economically unattractive relative to settlement or licensing terms.

References

No sources were provided or reliably citable within the prompt, so no references can be listed.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links